We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Safety of Testosterone Undecanoate i.m. in Hypogonadal Men

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00452322
Recruitment Status : Completed
First Posted : March 27, 2007
Last Update Posted : March 27, 2007
Information provided by:
University Hospital Muenster

Brief Summary:
Treatment of male hypogonadism by testosterone substitution has be monitored in terms of safety. This study relates to safety of a new long-acting preparation.

Condition or disease Intervention/treatment Phase
Hypogonadism Drug: Testosterone Substitution by Testosterone Undecanoate i.m. Phase 2

Detailed Description:

A reliable form of androgen substitution therapy regarding kinetics, tolerance and restoration of androgenicity is paramount in hypogonadal men. Intramuscular injection of the long-acting ester testosterone undecanoate (TU) offers a new modality.

The objective is to assess safety of TU regarding metabolic and pharmacogenetic confounders in hypogonadal men treated with this new formulation.

This is a longitudinal prospective one-arm open intervention and observation trial. A minimum of 5 individual assessments is a prerequisite. Investigated modulators of safety parameters entering regression models are: nadir and/or delta total testosterone concentrations, body mass index (BMI), and age.

The setting Andrological outpatient department.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Long-Term Intervention Phase 2 Study of Safety Aspects of Testosterone Undecanoate i.m. in Hypogonadal Men
Study Start Date : April 1997
Study Completion Date : January 2007

Primary Outcome Measures :
  1. Prostate (size, PSA-level)
  2. Erythropoeisis (Hemoglobin, Hematocrit)
  3. Lipoproteins (HDL, LDL, Triglycerides)
  4. Blood pressure
  5. Pulse

Secondary Outcome Measures :
  1. Possible changes of body mass index

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   17 Years to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men presenting hypogonadism-related symptoms and desiring substitution therapy. Such symptoms are fatigue, loss of libido, depressiveness, change in body composition/weight, decreased physical performance, decrease in aggressive behaviour, disability to cope, decreased work performance, lack of androgenization. At least one of these symptoms has to be accompanied by low total testosterone levels (< 12 nmol / L).
  • All patients have to give written informed consent for the use of their data for scientific evaluation as approved by the Ethics Committee of the Medical Faculty, University of Muenster, Germany and the State Medical Board.

Exclusion Criteria:

  • Prostate Cancer
  • Breast Cancer
  • Desired Paternity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00452322

Institute of Reproductive Medicine of the University Clinics
Muenster, Germany
Sponsors and Collaborators
University Hospital Muenster
Study Director: Eberhard Nieschlag, MD, PhD University Clinics Muenster, Germany

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00452322     History of Changes
Other Study ID Numbers: IRM 96/17
EK 78a/97Nie1
First Posted: March 27, 2007    Key Record Dates
Last Update Posted: March 27, 2007
Last Verified: March 2007

Keywords provided by University Hospital Muenster:

Additional relevant MeSH terms:
Gonadal Disorders
Endocrine System Diseases
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents